Products
Latest Partnered Companies
Projects

Estimated Cost :
US$1.05 billion
AstraZeneca Invests US$1.05 billion (£1bn) to Construct New R&D Facility
AstraZeneca plans for the construction of state-of-the-art research and development (R&D) facility with an investment of US$1.05 billion (£1bn). The n...

Estimated Cost :
-
Rentschler Biopharma Plans to Open New Manufacturing Center in Boston
Rentschler Biopharma plans to open new manufacturing site that will be an extension

Estimated Cost :
-
Artiva Biotherapeutics to Construct New Research and Manufacturing Center in Republic of Korea
Artiva Biotherapeutics plans to construct new GMP manufacturing center. The facility will be an addition to the Artiva’s continued research and GMP ma...

Estimated Cost :
CHF 850 million
Lonza Constructs Two Next-Generation Mammalian Manufacturing Facilities
Lonza invests US$927 million (CHF850 million) to construct two next-generation mammalian manufacturing facilities
Press Release
FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
Active Biotech AB today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech.
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Emergex Vaccines Holding Limited, a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s proprietary microneedle patch system
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
Ultragenyx Pharmaceutical Inc. and Abeona Therapeutics Inc. announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age. The booster dose
Events




Articles

Top 12 Analytical Lab Equipments in Pharmaceutical Industry
The analytical lab equipments or instruments are used in analytical applications in pharmaceutical, food-processing laboratories

A Complete Guide on Blister Packaging Machine
Packaging machinery is one of the vital equipment in the pharmaceutical industry, food processing, and chemical

Nanotechnology in Drug Delivery to Eyes, Skin, and Wounds Via Topical Route
One of the most favored courses for administering medications to eyes, skin, and wounds is the topical route. The principle objective for this

An Overview - Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredient (API) is the term used to refer to the biologically active component of a drug product

Next-Generation Biological Therapeutics Discovery & Development
Focus on drug discovery and development has shifted away from small to large, complex molecular entities